Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | MMP1 | P03956 | 1/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.63 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | MMP8 | P22894 | 1/20 | 0.63 |
| ▸ | MMP13 | P45452 | 1/20 | 0.63 |
| ▸ | F2 | P00734 | 2/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.58 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2039879 | 1.00 | KMT2A (1.00) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL11566827 | 1.00 | KMT2A (1.00) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL11589602 | 0.89 | KMT2A (0.79) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL2041279 | 0.88 | KMT2A (1.00) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL11226703 | 0.85 | KMT2A (0.80) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL8208093 | 0.85 | KMT2A (0.93) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL27749452 | 0.85 | KMT2A (0.80) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL2359170 | 0.85 | KMT2A (0.72) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL237684 | 0.84 | KMT2A (0.73) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL3194681 | 0.84 | POLB (0.74) | KMT2AMEN1CA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4444744-A1 | ARRDC1-MEDIATED MICROVESICLES (ARMMS) DEGRADING SYSTEM AND USES THEREOF | Vesigen, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023108089-A1 | ARRDC1-MEDIATED MICROVESICLES (ARMMS) DEGRADING SYSTEM AND USES THEREOF | Vesigen, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | KMT2A 2898/4885MEN1 2796/4885CA1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.